Related Experiment Video
Updated: May 6, 2026
12:43
Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
Published on: August 16, 2016
20.6K
Catecholamine levels and treatment in chronic heart failure
1Department of Cardiac Medicine, National Heart and Lung Institute, London, U.K.
European Heart Journal
|July 4, 1998
Summary
This review examines circulating adrenaline and noradrenaline levels in chronic heart failure. While these catecholamines predict prognosis, interventions affecting them don't always improve survival.
Area of Science:
- Cardiology
- Neuroendocrinology
Background:
- Neurohormonal activation, including plasma catecholamines, is a key feature of chronic heart failure.
- Elevated noradrenaline levels are established predictors of poor prognosis in heart failure patients.
Purpose of the Study:
- To review circulating adrenaline and noradrenaline levels across heart failure disease stages.
- To assess the relationship between catecholamine levels, interventions, and patient survival.
Main Methods:
- Literature review focusing on studies of circulating adrenaline and noradrenaline in heart failure.
- Analysis of how various drug and non-drug interventions impact catecholamine levels and survival outcomes.
Main Results:
- Catecholamine levels change significantly from myocardial infarction to severe chronic heart failure.
- Angiotensin converting enzyme (ACE) inhibitors show benefits in heart failure patients with high catecholamine levels.
- Interventions affecting catecholamine levels do not consistently correlate with improved patient survival.
Conclusions:
- The prognostic significance of catecholamine levels in heart failure is acknowledged.
- The clinical utility of spot catecholamine measurements is limited by newer prognostic markers.
- Further research may clarify the complex interplay between neurohormonal activation and heart failure management.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:29Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641
01:22Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635